Company Cellectis S.A.

Equities

ALCLS

FR0010425595

Biotechnology & Medical Research

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Holdings

Company contact information

Sector

Sales per Business

Sales per region

Ratings for Cellectis S.A.

Quarterly revenue - Rate of surprise

Sector Other Biotechnology & Medical Research

Market Closed - Euronext Paris Other stock markets 16:35:26 26/04/2024 BST			5-day change	1st Jan Change
2.345 ^EUR	-1.47%		-1.88%	-15.16%

04-26	European Equities Traded in the US as American Depositary Receipts Trend Higher in Friday Trading, End Week Up 3.4%	MT
04-25	European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Thursday Trading	MT

Cellectis S.A. is a clinical-stage biotechnology company using its pioneering TALEN® genome-editing technology to develop innovative therapies for the treatment of serious diseases. Cellectis S.A. is developing the first CAR-T cell-based allogeneic immunotherapy therapeutics, inventing the concept of off-the-shelf, ready-to-use engineered CAR-T cells for the treatment of cancer patients, and a platform for performing therapeutic genetic modifications in hematopoietic stem cells in a various diseases. Capitalizing on its 23 years of expertise in genome engineering, its TALEN® genome editing technology and its pioneering PulseAgile electroporation technology, Cellectis S.A. is developing innovative product candidates using the power of the immune system to treat diseases with unmet medical needs. As part of its commitment to the search for curative cancer therapies, Cellectis S.A. is developing UCART product candidates directed at the unmet medical needs of patients with certain types of cancer, including acute myeloid leukemia, B-cell acute lymphoblastic leukemia, and multiple myeloma. HEAL is a new platform focused on hematopoietic stem cells for the treatment of blood disorders, immune deficiencies, and lysosomal storage diseases.

Number of employees: 234

EUR in Million	2021	Weight	2022	Weight	Delta
Therapeutics 100.0 %	26	53.0 %	18	100.0 %	-28.95%

EUR in Million	2021	Weight	2022	Weight	Delta
France 100.0 %	26	53.0 %	18	100.0 %	-28.95%

Managers	Title	Age	Since
David Sourdive FOU	Founder	57	19/12/99
André Choulika FOU	Founder	59	19/12/99
Bing C. Wang DFI	Director of Finance/CFO	47	09/02/22
Mark Frattini CTO	Chief Tech/Sci/R&D Officer	58	31/07/20
Stephan Reynier CMP	Compliance Officer	55	31/03/11
Philippe Duchateau CTO	Chief Tech/Sci/R&D Officer	61	31/12/00
Arthur Stril IRC	Investor Relations Contact	35	30/06/18
Kyung Nam-Wortman HRO	Human Resources Officer	54	15/11/20
Steve Doares PRN	Corporate Officer/Principal	-	20/07/20
Marie-Bleuenn Terrier LAW	General Counsel	42	31/12/07

Members of the board	Title	Age	Since
Jean-Pierre Garnier CHM	Chairman	75	04/11/20
André Choulika FOU	Founder	59	19/12/99
David Sourdive FOU	Founder	57	19/12/99
Laurent Arthaud BRD	Director/Board Member	61	27/10/11
Pierre Bastid BRD	Director/Board Member	69	27/10/11
Axel-Sven Malkomes BRD	Director/Board Member	57	27/06/22
Donald Bergstrom BRD	Director/Board Member	52	27/06/22
Rainer Boehm BRD	Director/Board Member	63	28/06/17
Cécile Chartier BRD	Director/Board Member	-	26/06/23

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	55,583,768	55,583,768 ( 100.00 %)	0	100.00 %

Name	Equities	%	Valuation
ASTRAZENECA PLC 22.30 %	16,000,000	22.30 %	43 M €
Bpifrance Participations SA /PRIVATE EQUITY/ 8.186 %	5,873,247	8.186 %	16 M €
PFIZER, INC. 3.884 %	2,786,924	3.884 %	7 M €
Pierre Bastid 2.595 %	1,862,016	2.595 %	5 M €
Baillie Gifford & Co. 1.879 %	1,347,970	1.879 %	4 M €
André Choulika 1.388 %	996,034	1.388 %	3 M €
David Sourdive 1.370 %	983,035	1.370 %	3 M €
Financière Arbevel SA 0.1761 %	126,342	0.1761 %	339 486 €
Sunny Asset Management SA 0.1185 %	85,000	0.1185 %	228 398 €
Saint Olive Gestion SNC 0.1185 %	85,000	0.1185 %	228 398 €

Name	Equities	%	Valuation
Long Focus Capital Management LLC 6.254 %	4,487,293	6.254 %	12 M €
Capital Research & Management Co. (International Investors) 2.577 %	1,848,804	2.577 %	5 M €
Crédit Suisse Fund Management SA 2.005 %	1,438,255	2.005 %	4 M €
Baillie Gifford & Co. 1.138 %	816,643	1.138 %	2 M €
Principal Global Investors LLC 0.5570 %	399,627	0.5570 %	1 M €
Macquarie Investment Management Business Trust 0.3162 %	226,875	0.3162 %	601 219 €
KBC Asset Management NV 0.2278 %	163,447	0.2278 %	433 135 €
Oppenheimer & Co., Inc. 0.1856 %	133,143	0.1856 %	352 829 €
Jackson National Asset Management LLC 0.1627 %	116,754	0.1627 %	309 398 €
Morgan Stanley & Co. International Plc 0.1062 %	76,225	0.1062 %	201 996 €

Name	Equities	%	Valuation
CALYXTPAR 2.28%	479,264	2.28%	10,764,269 $

Cellectis SA

8, rue de la Croix Jarry

75013, Paris

+33 1 81 69 16 00

http://www.cellectis.com

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Other Biotechnology & Medical Research

	1st Jan change	Capi.
CELLECTIS S.A.	-15.16%	180M
IQVIA HOLDINGS INC.	+1.51%	42.75B
LONZA GROUP AG	+49.22%	41.61B
MODERNA, INC.	+8.57%	41.34B
CELLTRION, INC.	-12.36%	26.59B
ICON PUBLIC LIMITED COMPANY	+8.92%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.12B
MEDPACE HOLDINGS, INC.	+29.17%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.76B
UNITED THERAPEUTICS CORPORATION	+6.35%	11B

Other Biotechnology & Medical Research